BiotechTube

parsaclisinib + placebo

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia (wAIHA)

Conditions

Warm Autoimmune Hemolytic Anemia (wAIHA)

Trial Timeline

Mar 15, 2022 → Apr 29, 2024

NCT ID
NCT05073458

About parsaclisinib + placebo

parsaclisinib + placebo is a phase 3 stage product being developed by Incyte for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is terminated. This product is registered under clinical trial identifier NCT05073458. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).

What happened to similar drugs?

0 of 5 similar drugs in Warm Autoimmune Hemolytic Anemia (wAIHA) were approved

Approved (0) Terminated (0) Active (5)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05073458Phase 3Terminated

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34